Gong Sheng-Lan, Guo Meng-Qiao, Tang Gu-Sheng, Zhang Chun-Ling, Qiu Hui-Ying, Hu Xiao-Xia, Yang Jian-Min
Department of Hematology, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China.
Oncol Lett. 2016 Jan;11(1):770-774. doi: 10.3892/ol.2015.3949. Epub 2015 Nov 18.
Myeloid tumor possessing platelet-derived growth factor receptor β (PDGFRβ) gene rearrangement is a rare hematological malignancy, which presents with typical characteristics of myeloid proliferation disorders and eosinophilia. In the present study, an elderly chronic myelomonocytic leukemia patient was diagnosed with chromosome rearrangement. Fluorescence hybridization (FISH) was conducted with a PDGFRβ isolate probe, and gene translocation between PDGFRβ on chromosome 5 and genes on the chromosomes of group D (13-15) was detected. Karyotype analysis revealed a chromosome 5 break, and PDGFRβ-thyroid hormone receptor interactor 11 (CEV14) gene fusion was confirmed via reverse transcription-polymerase chain reaction (RT-PCR), which additionally revealed the chromosome rearrangement t(5;14)(q33;q32). Due to the correlation between PDGFRβ-CEV14 expression and effectiveness of treatment with tyrosine kinase inhibitors, this fusion gene is considered to be an oncogene. In the present study, an elderly patient was diagnosed with a myeloid tumor associated with the fusion gene PDGFRβ-CEV14, using the methods of FISH and RT-PCR. These methods were confirmed to be of significant value in improving diagnosis, guiding treatment and increasing the cure rate of patients, due to their ability to detect multiple rearrangement genes associated with PDGFRβ in myelodysplastic and myeloproliferative neoplasms.
具有血小板衍生生长因子受体β(PDGFRβ)基因重排的髓系肿瘤是一种罕见的血液系统恶性肿瘤,具有髓系增殖性疾病和嗜酸性粒细胞增多的典型特征。在本研究中,一名老年慢性粒单核细胞白血病患者被诊断出染色体重排。使用PDGFRβ分离探针进行荧光原位杂交(FISH),检测到5号染色体上的PDGFRβ与D组染色体(13 - 15)上的基因之间发生了基因易位。核型分析显示5号染色体断裂,通过逆转录聚合酶链反应(RT-PCR)证实了PDGFRβ-甲状腺激素受体相互作用因子11(CEV14)基因融合,此外还揭示了染色体重排t(5;14)(q33;q32)。由于PDGFRβ-CEV14表达与酪氨酸激酶抑制剂治疗效果之间的相关性,该融合基因被认为是一种癌基因。在本研究中,一名老年患者通过FISH和RT-PCR方法被诊断出患有与融合基因PDGFRβ-CEV14相关的髓系肿瘤。由于这些方法能够检测骨髓增生异常综合征和骨髓增殖性肿瘤中与PDGFRβ相关的多个重排基因,因此被证实对提高诊断、指导治疗和提高患者治愈率具有重要价值。